Sunitinib dose-escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications

Sunitinib is considered a first-line therapeutic option for patients with advanced clear cell renal cell carcinoma (ccRCC). Despite sunitinib clinical efficacy, eventually patients develop drug resistance and disease progression. Herein, we tested the hypothesis whether initial sunitinib resistance...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Mol Cancer Ther
Main Authors: Adelaiye, Remi, Ciamporcero, Eric, Miles, Kiersten Marie, Sotomayor, Paula, Bard, Jonathan, Tsompana, Maria, Conroy, Dylan, Shen, Li, Ramakrishnan, Swathi, Ku, Sheng-Yu, Orillion, Ashley, Prey, Joshua, Fetterly, Gerald, Buck, Michael, Chintala, Sreenivasulu, Bjarnason, Georg A., Pili, Roberto
Format: Artigo
Sprog:Inglês
Udgivet: 2014
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4326587/
https://ncbi.nlm.nih.gov/pubmed/25519701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0208
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker